A new test just told two out of three "high-risk" breast cancer patients something they never expected to hear: you don't need chemo.
No needles.
No hair loss.
No months of nausea.
Just hormone therapy — and the same survival odds.
Here's how we got here.
Back in 2005, researchers at the University of North Carolina, led by Charles Perou, started building a genomic test called Prosigna.
It scans 50 genes inside a tumour sample.
Out comes a single number — the ROR score — Risk Of Recurrence.
👉 Score above 60? Chemo, then hormone therapy.
👉 Score 60 or below? Hormone therapy. That's it.
Sounds simple.
Proving it safe took two decades.
Enter OPTIMA — a trial that quietly enrolled over 4,400 patients across the UK, Norway, Sweden, Australia, New Zealand and Thailand, all diagnosed with ER-positive, HER2-negative breast cancer.
That's the most common kind — about 70% of all breast cancer cases.
Everyone in the trial had already been told: you need chemo.
The test was there to check — were the doctors right for everyone, or just some.
68% of these high-risk patients were cleared to skip chemotherapy entirely.
Their five-year cancer-free survival rate?
93.7%.
And when researchers presented the full comparison at ASCO earlier this year, the gap was almost nothing:
For the patients spared chemo, the math is brutal in its honesty — chemotherapy would have prevented, at most, two extra recurrences for every 100 women treated.
That's the price of subjecting the other 98 to needless toxicity.
This isn't just fewer side effects.
It's a rethink of who "high risk" really means.
The test worked just as well for groups doctors usually treat with extra caution — premenopausal women, and patients with cancer in multiple lymph nodes.
Biology, it turns out, is a better guide than assumption.
For decades, "high risk" meant one thing: more chemo.
Now it might just mean: look closer first.
That's all for now!
